PLEASANTON, Calif., Dec. 1 The new position of Executive Vice President, Commercial Affairs at Microchip Biotechnologies, Inc. has been taken up by Howard Goldstein, a biotech lab systems executive with more than 30 years of experience creating and managing life science product organizations. Mr. Goldstein will direct Microchip Biotechnologies' marketing, business development, sales and customer service operations as the company makes the transition from product development to full commercial operations.
"Howard adds directly relevant strategic, operational, and commercial experience to our executive profile," said Stevan Jovanovich, President/CEO of Microchip Biotechnologies. "His leadership and expertise will be keys to the realization of our commercial growth objectives."
Prior to joining Microchip Biotechnologies, Mr. Goldstein first served as Chief Executive Officer and then Chief Commercial Officer of Arcxis Biotechnologies, and was Managing Partner of Practical Marketing and Sales, a biotech business consultancy. He has been responsible for building and directing marketing, engineering, and sales teams that have created more than 10 key product categories in the research marketplace. Mr. Goldstein received his MBA degree in Organizational Development from Temple University, Philadelphia, PA and an M.Sc. degree in Biochemistry from the University of Dayton, Dayton OH.
About Microchip Biotechnologies, Inc.
Microchip Biotechnologies, Inc. (MBI), headquartered in Pleasanton, CA is a venture-backed, privately held company that produces automated sample processing systems for life sciences, applied sciences, and healthcare diagnostics markets. The company's products are based on the Apollo fluidics technology platform, which integrates advanced fluidics and analytical capabilities to produce automated sample-to-answer systems for DNA and RNA sequencing, DNA-based forensics and human identity (HID) testing, biodefense, and molecular diagnostics applications. The company's first product, the Apollo 100 System, automates sample processing for Sanger cycle sequencing and dramatically reduces process requirements for expensive sequencing reagents. For additional information about MBI, visit http://www.microchipbiotech.com.
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
Contact: Howard D. GoldsteinMicrochip Biotechnologies Inc.5720 Stoneridge Drive, Suite 300Pleasanton, CA 94568(925) firstname.lastname@example.org
SOURCE Microchip Biotechnologies, Inc.